George Church is an angel investor and operator angel based in Boston, Massachusetts, United States with 3 known investments: Orchid, heXem bio and Thymmune Therapeutics.
Is George Church a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
- Stage
- Seed
- Sector
- Healthcare
Contacts
George Church portfolio companies (3)
- Orchid
- heXem bio
- Thymmune Therapeutics
Affiliated funds' portfolios
Professor at HMS MEDscience, whose known portfolio counts 2 companies
- Marvin AI
- Sherbit
Investor Profile
The listing covers sector Healthcare, and focus areas Biotech, Gene Therapy and Genomics. Startups operating in these areas may find George Church relevant.
George Church appears in Seed rounds across the known deals.
The portfolio and focus above give founders context on whether George Church matches their raise.
Colleagues at HMS MEDscience
Halle Tecco
Adjunct Faculty / Course Director
London, United Kingdom
Erika Pabo
Faculty
Boston, United States
Raju Kucherlapati
Professor
Weston, United States
Genghis Lloyd-Harris
Reviewer
London, United Kingdom
Jeffrey Leerink
Board of Fellows
Boston, United States
David Walt
Hansjörg Wyss Professor of Biologically Inspired Engineering
Boston, United States
Mason Freeman
Investor
Boston, United States
Iñaki Arango
Investor
Cambridge, United States
Joan Brugge
Investor
Boston, United States
Gary Gottlieb
Professor Of Psychiatry
Boston, United States
G. Scott Gazelle
Professor of Radiology
Boston, United States
Greg Erman
Investor
Boston, United States
Similar investors
Showing 18 of 98
Andrew Sandford
angel investor
Boston, United States
Michael Chambers
angel investor and operator angel
Fargo, United States
Ken Cheng
angel investor and operator angel
San Francisco, United States
Anurag Agarwal
angel investor and operator angel
Philadelphia, United States
Vik Bajaj
angel investor and operator angel
United States
Zen Chu
angel investor
Yury Kukushkin
angel investor
Boston, United States
Michael Curtis
angel investor and operator angel
Waltham, United States
Demis Hassabis
Co-Founder & CEO
London, United Kingdom
Trevor Martin
angel investor and operator angel
San Francisco, United States
John Evans
angel investor and operator angel
Cambridge, United States
Timothy Springer
angel investor and operator angel
Boston, United States
Garri Zmudze
General partner
Beverly Hills, United States
David Wiersma
angel investor
Tucson, United States
Michael Henry
Member
Berkeley, United States
Chris Leiter
Founder & General Partner
San Francisco, United States
Jennifer Doudna
angel investor
Berkeley, United States
Jeff Huber
angel investor and operator angel
Seattle, United States
Frequently asked questions
Who is George Church?
George Church is an angel investor and operator angel based in Boston, Massachusetts, United States with 3 known investments on file, among them Orchid, heXem bio and Thymmune Therapeutics. The sections above list the sectors, stages and firms attached to that record.
What does George Church invest in?
Listed sectors include Healthcare; listed focus areas include Biotech, Gene Therapy and Genomics. Those tags come from the companies attached to this profile, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does George Church invest at?
The known deals of George Church include Seed rounds. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is George Church listed at?
George Church is listed as Professor at HMS MEDscience. 12 other people in the database share a firm with George Church.
How do I contact George Church?
An email address, a phone number and a LinkedIn page are on file for George Church. The address stays masked on this page and is readable inside RaiseHunt after you create an account.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal